Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital Article 223-16 of the General Regulations…
Categorie
Financial
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR…
November 14, 2025
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR…
November 13, 2025
MaaT Pharma Reports Financial Results for the Third Quarter 2025 and Provides Financing Update The Company received an upfront payment…
November 4, 2025
MaaT Pharma Publishes its Half Year 2025 Results and Provides a Business Update Positive results from Phase 3 trial for…
September 17, 2025
MaaT Pharma Secures €37.5 Million Loan From European Investment Bank (EIB) Marking a New Step in Advancing its Clinical Program…
July 28, 2025
MaaT Pharma: Half-year Report to the Liquidity Contract With Kepler Cheuvreux Lyon, France, July 24, 2025 – 6:00pm CET –…
July 24, 2025
Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital Article 223-16 of the General…
July 7, 2025
MaaT Pharma Presents the Results of its Annual Ordinary and Extraordinary General Meeting Lyon, France, June 24, 2025 – 8:00pm…
June 24, 2025
MaaT Pharma Provides a Business Update and Highlights Key Milestones Expected in 2025 Marketing Authorization application of Xervyteg® (MaaT013) in…
June 19, 2025
We are a clinical-stage microbiome therapeutics company aiming to improve survival in cancer.
Ressources
Contact
Nous sommes une société au stade clinique, spécialisée dans les thérapies issues du microbiote dédiées aux patients atteints de cancer.
Contact
Nous sommes une société au stade clinique, spécialisée dans les thérapies issues du microbiote dédiées aux patients atteints de cancer.